Cellexus updates on pipeline

The UK's Cellexus, a company which develops and commercializes novel single-use bioreactors and cell-based technologies for biopharmaceutical research and production, has notified investors of products that will be launched in the coming months.

These include, the CellMaker Regular for culture of escherichia coli and Pichia cells and the CellMaker PLUS for culture of all cells including mammalian and insect. The new systems are designed for improved performance to achieve higher yields of soluble protein using the single-use CellexusBag. In addition, the company is developing a range of peripheral products, including those for sampling and oxygen generation, which it says will further facilitate system use and performance in an even broader range of conditions.

Cellexus was formed when investors acquired the assets of Cellexus Biosystems, including its intellectual property, in April, and have since set up a new management team to bring the company's technologies and products to market.